摘要号：1020    

ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).  

ACE-Breast-02：新型靶向HER2的抗体药物偶联物(ADC)ARX788+拉帕替尼+卡培他滨治疗HER2阳性晚期乳腺癌(ABC)的关键II/III期试验

讲者：胡夕春教授  复旦大学附属肿瘤医院

摘要号：104

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.    

Sacituzumab tirumotecan (SKB264/MK-2870)用于经治局部复发或转移性三阴性乳腺癌(TNBC)患者：OptiTROP-Breast01 III期研究结果

讲者：樊英教授 中国医学科学院肿瘤医院

摘要号：6002  

Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.    

恩度联合同步放化疗 vs 仅同步放化疗治疗局部晚期鼻咽癌(LA-NPC)：一项III期、前瞻性、随机对照、多中心临床试验

讲者：康敏教授 广西医科大学第一附属医院 

摘要号：6001    

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.    

替雷利珠单抗 vs 安慰剂联合诱导化疗，随后同步放化疗和替雷利珠单抗或安慰剂辅助治疗局部区域性晚期鼻咽癌：多中心，随机，安慰剂对照，双盲，3期试验中期分析结果

讲者：陈秋燕教授 中山大学肿瘤防治中心

摘要号：LBA6000    

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.    

卡瑞利珠单抗辅助治疗高危局部区域性晚期鼻咽癌(DIPPER)：一项多中心、开放标签、3期随机对照试验

讲者：刘需教授 中山大学肿瘤防治中心

摘要号：6013  

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.    
评估普特利单抗联合表皮生长因子受体-ADC (EGFR-ADC)药物MRG003治疗EGFR阳性实体瘤患者安全性和有效性的I/II期研究初步结果

讲者：阮丹云教授 中山大学肿瘤防治中心
  
摘要号：LBA6018

Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial.

共价FAPI PET促进甲状腺髓样癌精准管理：一项前瞻性、单臂临床试验

讲者：孔梓任教授 中国医学科学院肿瘤医院 

摘要号：6011   

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.    

信迪利单抗+含铂双药化疗后经口机器人手术治疗HPV相关可切除口咽癌：单臂，II期试验

讲者：宋明教授 中山大学肿瘤防治中心

摘要号：LBA7003

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

西达本胺联合R-CHOP用于初治MYC和BCL2双表达弥漫性大B细胞淋巴瘤：III期DEB研究中期分析结果

讲者：赵维莅教授 上海血液学研究所 

摘要号：6505   

Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.  

新型CD3xCD19 IgG4双特异性抗体CN201用于复发或难治性B细胞急性淋巴细胞白血病成年患者的I期研究

讲者：王迎教授 中国医学科学院血液学研究所

摘要号：7002

CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.  

CLAMP：卡瑞利珠单抗联合培门冬酶、依托泊苷和高剂量甲氨蝶呤治疗自然杀伤(NK)/ T细胞淋巴瘤的II期前瞻性研究

讲者：刘涛教授 华中科技大学同济医学院附属协和医院 

摘要号：6510

Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).    

IMM01联合阿扎胞苷(AZA)用于成人高危骨髓增生异常综合征(MDS)一线治疗的2期研究最新结果

讲者：杨威教授 中国医科大学附属盛京医院
 
摘要号：6515     

CD7-CAR-T细胞治疗复发/难治性淋巴细胞白血病/淋巴瘤的安全性和有效性：I期剂量递增/扩展研究

讲者：胡利娟教授 北京大学人民医院

摘要号：7511        

OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).    
OriCAR-017，一种新型靶向GPRC5D的CAR-T，用于复发/难治性多发性骨髓瘤：1期研究(POLARIS)长期随访结果

讲者：付珊教授 浙江大学医学院附属第一医院

摘要号：7017

Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.    

Timdarpacept (IMM01)联合替雷利珠单抗用于既往抗PD-1单抗治疗失败经典型霍奇金淋巴瘤：一项评估安全性和初步抗肿瘤活性得开放标签、多中心、II期研究(IMM01-04)

讲者：Zhenjiu Wang  

摘要号：3505    

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.   

IBI310(抗CTLA-4抗体)+信迪利单抗(抗PD-1抗体)新辅助治疗微卫星不稳定性高/错配修复缺陷结直肠癌：一项随机、开放标签、Ib期研究结果

讲者：徐瑞华教授 中山大学肿瘤防治中心

摘要号：3516   

Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial.    

直肠癌经肛 vs 腹腔镜全直肠系膜切除术(TaLaR)后3年无病生存率：一项随机临床试验

讲者：康亮教授 中山大学附属第六医院

摘要号：3514    

Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.    

通过腹腔或静脉输注低氧反应性CEA CAR-T细胞治疗用于重度预处理实体瘤患者的I期试验

讲者：Hangyu Zhang  浙江大学医学院附属第一医院  

摘要号：LBA3511

Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.   

全程新辅助长程放疗 vs 同步放化疗用于具有高危因素的局部晚期直肠癌新辅助治疗(TNTCRT)：一项多中心、随机、开放标签3期试验。

讲者：王辛教授 四川大学华西医院 

摘要号：4012    

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.    
卡度尼利单抗联合pulocimab和紫杉醇用于免疫化疗失败的晚期胃或胃食管交界(G/GEJ)癌患者二线治疗的有效性和安全性：一项多中心、双盲、随机试验

讲者：张小田教授 北京大学肿瘤医院

摘要号：4019

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).  

GPC3C-TGFβRIIDN装甲型CAR-T疗法用于晚期肝细胞癌(HCC)患者的I期研究

讲者：章琦教授 浙江大学医学院附属第一医院

摘要号：4009

Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).   
维迪西妥单抗(RC48)联合替雷利珠单抗和S-1用于HER2过表达晚期胃或胃食管交界腺癌一线治疗的疗效：一项多中心、单臂、II期试验(RCTS)

讲者：刘联教授 山东大学齐鲁医院

摘要号：4010   

A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study
一种新型、独特性设计的抗PD-L1和4-1BB双特异性抗体(LBL-024)用于晚期恶性肿瘤和神经内分泌肿瘤：I/II期、开放标签、多中心、剂量递增/扩展研究中LBL-024单药治疗的安全性和有效性结果

讲者：张盼盼教授 北京大学肿瘤医院

摘要号：4011  

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.    

抗CLDN18.2/CD3双特异性抗体IBI389用于晚期胰腺导管腺癌的安全性和有效性：I期初步结果

讲者：郝继辉教授 天津医科大学肿瘤医院

摘要号：4511    

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial.    

卡瑞利珠单抗联合阿帕替尼用于经治晚期肾上腺皮质癌：单臂，开放标签，2期试验

讲者：卫治功(彭星辰教授团队） 四川大学华西医院

摘要号：2007    

High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.

高剂量阿美替尼用于CNS转移的初治EGFR突变NSCLC：疗效和生物标志物分析

讲者：范云教授 浙江省肿瘤医院

摘要号：2003

Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.    

伯瑞替尼用于具有PTPRZ1-METFUsion GENe(FUGEN)的经治继发性胶质母细胞瘤/IDH突变型胶质母细胞瘤的疗效和安全性:一项随机、多中心、开放标签、II/III期试验。

讲者: 保肇实教授 首都医科大学附属北京天坛医院

摘要号：11502

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma

olverembatinib (HQP1351)治疗酪氨酸激酶抑制剂(TKI)耐药琥珀酸脱氢酶(SDH)缺陷型胃肠间质瘤(GIST)和副神经节瘤的最新疗效结果

讲者：邱海波教授 中山大学肿瘤防治中心

摘要号：11507    

ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.    

ARTEMIS-002: HS-20093用于复发或难治性骨肉瘤患者的2期研究

讲者：谢璐教授 北京大学人民医院

摘要号：11505    

Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial.  

信迪利单抗、多柔比星和异环磷酰胺(AI)用于晚期未分化多形性肉瘤(UPS)、滑膜肉瘤(SS)、黏液样脂肪肉瘤(MLPS)和去分化脂肪肉瘤(DDLPS)一线治疗：一项单臂2期试验

讲者：罗志国教授 复旦大学附属肿瘤医院 

摘要号：11518

Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).    

NB003，一种广谱KIT/PDGFRα抑制剂，用于晚期胃肠道间质瘤(GIST)患者的I期研究

讲者：李健教授 北京大学肿瘤医院

摘要号：11515

A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts.  

安罗替尼和抗PD-1抗体治疗肺泡软组织肉瘤的II期研究：扩展队列结果

讲者：谭智超教授 北京大学肿瘤医院

摘要号：12013

Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial.  

护士主导的多学科治疗对头颈肿瘤患者的影响：一项随机对照试验

讲者：王菁菁（彭星辰教授团队)  四川大学华西医院